Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPension (IS)Profit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Harvard Bioscience (HBIO) Shares Outstanding (Weighted Average) (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Shares Outstanding (Weighted Average) for 15 consecutive years, with $43.5 million as the latest value for Q4 2024.

  • On a quarterly basis, Shares Outstanding (Weighted Average) rose 2.64% to $43.5 million in Q4 2024 year-over-year; TTM through Dec 2024 was $43.5 million, a 2.64% increase, with the full-year FY2024 number at $43.5 million, up 2.64% from a year prior.
  • Shares Outstanding (Weighted Average) was $43.5 million for Q4 2024 at Harvard Bioscience, up from $42.4 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $43.5 million in Q4 2024 to a low of $38.3 million in Q1 2020.
  • A 5-year average of $40.2 million and a median of $40.2 million in 2021 define the central range for Shares Outstanding (Weighted Average).
  • Peak YoY movement for Shares Outstanding (Weighted Average): increased 1.82% in 2020, then grew 4.41% in 2021.
  • Harvard Bioscience's Shares Outstanding (Weighted Average) stood at $38.6 million in 2020, then increased by 4.41% to $40.3 million in 2021, then increased by 2.65% to $41.4 million in 2022, then increased by 2.43% to $42.4 million in 2023, then increased by 2.64% to $43.5 million in 2024.
  • Per Business Quant, the three most recent readings for HBIO's Shares Outstanding (Weighted Average) are $43.5 million (Q4 2024), $42.4 million (Q4 2023), and $41.4 million (Q4 2022).